Glucose News and Research

RSS

Semaglutide significantly reduces obesity in treatment-resistant young adults

A weekly dose of semaglutide (2.4 mg) leads to a clinically significant reduction in body mass index (BMI) and related health outcomes in young adults with severe obesity who are treatment resistant following hospital-based non-pharmacological obesity care during childhood, according to a randomized controlled trial being presented at this year's European Congress on Obesity (ECO) in Istanbul, Turkey (12-15 May).

13 May 2026

GLP-1 obesity drugs mainly reduce fat while preserving muscle mass

New research to be presented at the European Congress on Obesity (ECO2026) in Istanbul, Turkey (12–15 May) shows that following treatment with GLP-1 drugs for obesity, most weight loss is fat mass (80–85%) and relative muscle mass is preserved.

13 May 2026

Gut microbes may reveal why diabetes raises heart disease risk

Integrated gut microbiome and plasma metabolomics profiling identified distinct microbial and metabolic signatures in people with T2DM and T2DM-CAD. In a small exploratory cohort, Bacteroides sp._CAG_875 and 12-ketoLCA emerged as candidate markers that may help distinguish diabetic patients with coronary complications, pending larger validation.

13 May 2026

Once-daily orforglipron helps preserve weight loss after semaglutide or tirzepatide

Oral orforglipron helped adults maintain clinically meaningful weight loss after prior injectable tirzepatide or semaglutide therapy. The phase 3b ATTAIN-MAINTAIN trial suggests switching to once-daily oral therapy may help reduce weight regain when injectable treatment is discontinued.

13 May 2026

Global effort redefines the most common hormonal disorder in women

A global effort led by Monash University has changed the name of a significant women's health condition that was misunderstood to be 'all about ovarian cysts'.

13 May 2026

Large human islet study reveals new insights into diabetes risk

Diabetes is the most common and serious chronic disease worldwide, characterized by insufficient insulin to maintain proper blood glucose levels.

12 May 2026

Could GLP-1 drugs help breast cancer patients live longer?

A large retrospective cohort study of adult female breast cancer patients found that GLP-1 receptor agonist use was associated with better all-cause survival and recurrence-free survival in patients with obesity or type 2 diabetes. The strongest associations were seen versus non-use in obesity and versus insulin or metformin in type 2 diabetes, while comparisons with SGLT2 inhibitors were less consistent and require further study.

12 May 2026

Maternal insulin resistance linked to higher abdominal fat in girls

Girls born to mothers with higher insulin resistance during the third trimester are more likely to have more abdominal fat at age 7, according to research presented at the 28th European Congress of Endocrinology in Prague.

12 May 2026

Cannabis compounds may improve metabolism and reduce diabetes risk

A University of California, Riverside preclinical study is shedding light on a long-observed but poorly understood phenomenon: chronic cannabis users tend to have lower body weight and a reduced risk of developing type 2 diabetes, despite the drug's well-known tendency to increase appetite.

11 May 2026

Two leading heart risk tools pass a major global test

A multinational Nature Medicine validation study found that PREVENT and SCORE2 cardiovascular risk equations performed generally well across 6.4 million people from observational cohorts and randomized trials. The findings support broader use of these tools for CVD risk stratification, while highlighting the need for local calibration and more validation in underrepresented regions.

11 May 2026

Partners of women with gestational diabetes face higher health risks

Partners of women with gestational diabetes have more health-related risk factors and morbidity than partners of women without gestational diabetes.

11 May 2026

Diabetes, weight-loss drugs not a perfect fit?

Type 2 diabetes affects millions of people worldwide and now a new international study, jointly led by Adelaide University, University of Oxford, ETH Zurich, and Stanford University, has found one in ten people may not be benefiting from common medications used to treat the condition.

11 May 2026

Urges for cardiologists to screen patients for UPF intake

The European Society of Cardiology identifies ultra-processed foods as a key cardiovascular risk, urging a shift in dietary guidelines for better heart health.

11 May 2026

Semaglutide shows sustained weight loss benefits in older adults

A new analysis of the STEP trails carried out by semaglutide manufacturer Novo Nordisk has analysed various trials to show the safety and efficacy of the obesity drug semaglutide in older adults (over 65 years), and found similar efficacy and safety as in the general trial populations .

11 May 2026

Greater weight loss from GLP-1 drugs lowers health complication risk

New research to be presented at this year's European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) shows that, following treatment for obesity or diabetes or both using incretin-based drugs, losing more weight versus less weight, and losing a little weight versus gaining weight, both lead to relatively lower risk of obesity-related conditions.

10 May 2026

Targeted mitochondrial therapy accelerates healing of diabetic chronic wounds

Impaired mitophagy and the accumulation of damaged mitochondria are key drivers of endothelial cell (EC)dysfunction in diabetic wounds.

10 May 2026

Liver fat may disrupt post-meal glucagon control in early type 2 diabetes

Researchers found that MASLD, rather than type 2 diabetes alone, was linked to higher fasting glucagon levels in adults with newly diagnosed diabetes and matched controls. In people with early type 2 diabetes, higher liver fat was specifically associated with exaggerated early post-meal glucagon responses, independent of insulin sensitivity, visceral fat, amino acids, or NEFAs.

10 May 2026

Insulin-dependent diabetes linked to sharply higher dementia risk

Individuals with diabetes are at an increased risk of developing dementia but those with insulin-requiring type 2 diabetes and type 1 diabetes have the greatest risk, according to research presented at the 28th European Congress of Endocrinology in Prague.

8 May 2026

Metformin targets the gut instead of the liver to lower glucose

For decades, physicians and scientists thought metformin, the leading Type 2 diabetes medication taken by millions worldwide, mainly targets the liver to suppress glucose production.

8 May 2026

Time-restricted eating helps with adherence in diabetes patients

Time-restricted eating shows promise for type 2 diabetes management, with family support and simple rules aiding adherence and metabolic health improvements.

8 May 2026